Troriluzole
Small molecule
Evidence outlook · regulatory review
Spinocerebellar Ataxia: application under FDA review
FDA accepts the troriluzole (Vyglxia) NDA resubmission for SCA (2026-10-22). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
NCT03701399: Randomized, quadruple-blind and placebo-controlled, but the primary measure (change in f-SARA ataxia score at week 48 in all participants) was not significantly different from placebo (difference -0.06, p=0.7581). A favourable difference in the SCA3 genetic subgroup (p=0.0450) does not change the result of the main comparison.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03701399 NCT03701399 · Spinocerebellar Ataxia Randomized, quadruple-blind and placebo-controlled, but the primary measure (change in f-SARA ataxia score at week 48 in all participants) was not significantly different from placebo (difference -0.06, p=0.7581). A favourable difference in the SCA3 genetic subgroup (p=0.0450) does not change the result of the main comparison. Registry: NCT03701399 | 3 | Randomization Phase: Change From Baseline in the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Total Score at Week 48 in SCA Participants (Randomization Baseline; Week 48) 2022-02-18 | Change in f-SARA total score at week 48, all SCA participants: troriluzole +0.20 vs placebo +0.27, difference -0.06 (95% CI -0.47 to 0.34), p=0.7581 (n=94 and 95); SCA3 subgroup -0.56 (95% CI -1.11 to -0.01), p=0.0450 (CT.gov posted results). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Troriluzole to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent